Since conventional antibiotics are almost ineffective on methicillin-resistant Staphylococcus aureus (MRSA) strains, designing their antibacterial alternatives is necessary. Besides, the use of vancomycin is applied for specific detection of the bacteria. Silver-incorporated vancomycin-modified mesoporous silica nanoparticles (MSNs@Van@Ag NPs) were designed for detection and treatment of MRSA bacteria. Mesoporous silica nanoparticles (MSNs) were synthesized through the template method, modified with vancomycin, and finally incorporated with silver nanoparticles (Ag NPs). The MSNs@Van@Ag NPs with a homogenously spherical shape, average size of 50-100 nm, surface area of 955.8 m2/g, and thermal stability up to 200°C were successfully characterized. The amount of Ag incorporated into the MSNs@Van@Ag was calculated at 3.9 ppm and the release amount of Ag was received at 2.92 ppm (75%) after 100 h. The in vitro antibacterial susceptibility test showed the MIC of 100 μg mL−1 for MSNs@Van and 50 μg mL−1 for MSNs@Van@Ag, showing in vitro enhanced effect of Ag and vancomycin in the bactericidal process. An in vivo acute pneumonia model was performed and biochemical assays and pathological studies confirmed the nanomedicine’s short-term safety for in vivo application. Cytokine assay using ELISA showed that MSN@Van@Ag causes a reduction of pro-inflammatory cytokines and bacterial proliferation leading to alleviation of inflammatory response.
Prados de la EscosuraL. Health, income, and the preston curve: a long view. Econ Hum Biol2023; 48: 101212.
2.
GavzySJScaleaJR. Organ transportation innovations and future trends. Curr Transplant Rep2022; 9: 143–147.
3.
NajjarR. Redefining radiology: a review of artificial intelligence integration in medical imaging. Diagnostics2023; 13: 2760.
4.
TroisiMAndreanoESalaC, et al.Vaccines as remedy for antimicrobial resistance and emerging infections. Curr Opin Immunol2020; 65: 102–106.
5.
WangHChenDLuH. Anti-bacterial monoclonal antibodies: next generation therapy against superbugs. Appl Microbiol Biotechnol2022; 106: 3957–3972.
6.
ChamaniMKhoshkhatPDorkooshFA. Telemedicine. In: SaharanVA (ed). Computer aided pharmaceutics and drug delivery: an application guide for students and researchers of pharmaceutical sciences. Singapore: Springer Nature Singapore, 2022, pp. 623–640.
7.
CavaillonJMSingerMSkireckiT. Sepsis therapies: learning from 30 years of failure of translational research to propose new leads. EMBO Mol Med2020; 12: e10128.
8.
ReynoldsDBurnhamJPVazquez GuillametC, et al.The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic. Eur Respir Rev2022; 31: 220068. DOI: 10.1183/16000617.0068-2022.
9.
GolliALCristeaOMZlatianO, et al.Prevalence of multidrug-resistant pathogens causing bloodstream infections in an intensive care unit. Infect Drug Resist2022; 15: 5981–5992. DOI: 10.2147/idr.s383285.
10.
GargSSDubeyRSharmaS, et al.Biological macromolecules-based nanoformulation in improving wound healing and bacterial biofilm-associated infection: a review. Int J Biol Macromol2023; 247: 125636. DOI: 10.1016/j.ijbiomac.2023.125636.
11.
González-BelloC. Antibiotic adjuvants–A strategy to unlock bacterial resistance to antibiotics. Bioorg Med Chem Lett2017; 27: 4221–4228.
12.
RobertsCABuikstraJE. Chapter 11 - bacterial infections. In: BuikstraJE (ed). Ortner’s identification of pathological conditions in human skeletal remains. 3rd ed.San Diego, CA: Academic Press, 2019, pp. 321–439.
13.
VentolaCL. The antibiotic resistance crisis: part 1: causes and threats. P T2015; 40: 277–283.
14.
RautSBajracharyaKAdhikariJ, et al.Prevalence of methicillin resistant Staphylococcus aureus in lumbini medical college and teaching hospital, palpa, western Nepal. BMC Res Notes2017; 10: 187. DOI: 10.1186/s13104-017-2515-y.
15.
Boyle-VavraSDaumRS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin. Lab Invest2007; 87: 3–9.
16.
EnrightMCRobinsonDARandleG, et al.The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA2002; 99: 7687–7692.
17.
XieJZhouMQianY, et al.Addressing MRSA infection and antibacterial resistance with peptoid polymers. Nat Commun2021; 12: 5898. DOI: 10.1038/s41467-021-26221-y.
18.
ZhangHYangFZhangQ, et al.Structural evolution of palygorskite as the nanocarrier of silver nanoparticles for improving antibacterial activity. ACS Appl Bio Mater2022; 5: 3960–3971. DOI: 10.1021/acsabm.2c00482.
19.
XiongJZhangLYuL, et al.Using laser etched-array periodic structure surface to construct silver loaded titanium implants with combined efficient antibacterial and osteogenic properties. Appl Surf Sci2023; 641: 158533, DOI: 10.1016/j.apsusc.2023.158533.
20.
XuZZhangCWangX, et al.Release strategies of silver ions from materials for bacterial killing. ACS Appl Bio Mater2021; 4: 3985–3999.
21.
StabrylaLMJohnstonKAMillstoneJE, et al.Emerging investigator series: it's not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity. Environ Sci Nano2018; 5: 2047–2068.
22.
Abu-DiefAMAlsehliMAl-EniziA, et al.Recent advances in mesoporous silica nanoparticles for targeted drug delivery applications. Curr Drug Deliv2022; 19: 436–450.
23.
Vallet-RegíMSchüthFLozanoD, et al.Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chem Soc Rev2022; 51: 5365–5451.
24.
ManzanoMVallet‐RegíM. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater2020; 30: 1902634.
25.
ZhuangJYuYLuR. Mesoporous silica nanoparticles as carrier to overcome bacterial drug resistant barriers. Int J Pharm2023; 631: 122529. DOI: 10.1016/j.ijpharm.2022.122529.
26.
HeYLuoLLiangS, et al.Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery. J Biomater Appl2017; 32: 524–532.
27.
MemarMYYekaniMGhanbariH, et al.Antimicrobial and antibiofilm activities of meropenem loaded-mesoporous silica nanoparticles against carbapenem-resistant Pseudomonas aeruginosa. J Biomater Appl2021; 36: 605–612. DOI: 10.1177/08853282211003848.
28.
GuptaJQuadrosMMominM. Mesoporous silica nanoparticles: synthesis and multifaceted functionalization for controlled drug delivery. J Drug Deliv Sci Technol2023; 81: 104305.
29.
HeSGuiJXiongK, et al.A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnol2022; 20: 101.
30.
KumariRNarviSSDuttaPK. Synthesis of chitosan succinate-g-amine functionalized mesoporous silica: inorganic-organic nanohybrid for antibacterial assessment, antioxidant activity and pH-controlled drug delivery. Int J Biol Macromol2023; 234: 123763. DOI: 10.1016/j.ijbiomac.2023.123763.
31.
OtalvaroJOÁlvarezTRGurovicMSV, et al.Magnetic mesoporous silica nanoparticles for drug delivery systems: synthesis, characterization and application as norfloxacin carrier. J Pharmaceut Sci2022; 111: 2879–2887. DOI: 10.1016/j.xphs.2022.05.024.
32.
TarnDAshleyCEXueM, et al.Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res2013; 46: 792–801.
33.
AatiSAnejaSKassarM, et al.Silver-loaded mesoporous silica nanoparticles enhanced the mechanical and antimicrobial properties of 3D printed denture base resin. J Mech Behav Biomed Mater2022; 134: 105421. DOI: 10.1016/j.jmbbm.2022.105421.
34.
ChoiYHwangJHLeeSY. Recent trends in nanomaterials-based colorimetric detection of pathogenic bacteria and viruses. Small Methods2018; 2: 1700351.
35.
KurczewskaJSawickaPRatajczakM, et al.Vancomycin-modified silica: synthesis, controlled release and biological activity of the drug. Int J Pharm2015; 486: 226–231. DOI: 10.1016/j.ijpharm.2015.04.005.
36.
DhandaGSarkarPSamaddarS, et al.Battle against vancomycin-resistant bacteria: recent developments in chemical strategies. J Med Chem2018; 62: 3184–3205.
37.
StogiosPJSavchenkoA. Molecular mechanisms of vancomycin resistance. Protein Sci2020; 29: 654–669.
38.
FengXMengXXiaoF, et al.Vancomycin-dendrimer based multivalent magnetic separation nanoplatforms combined with multiplex quantitative PCR assay for detecting pathogenic bacteria in human blood. Talanta2021; 225: 121953.
39.
Montelongo-PeraltaLLeón-BuitimeaAPalma-NicolásJ, et al.Antibacterial Activity of combinatorial treatments composed of transition-metal/antibiotics against Mycobacterium tuberculosis. Sci Rep2019; 9: 5471–5476.
40.
NiCZhongYWuW, et al.Co-delivery of nano-silver and vancomycin via silica nanopollens for enhanced antibacterial functions. Antibiotics2022; 11: 685.
41.
MaKDongPLiangM, et al.Facile assembly of multifunctional antibacterial nanoplatform leveraging synergistic sensitization between silver nanostructure and vancomycin. ACS Appl Mater Interfaces2020; 12: 6955–6965.
42.
PourjavadiATehraniZM. Mesoporous silica nanoparticles (MCM-41) coated PEGylated chitosan as a pH-responsive nanocarrier for triggered release of erythromycin. International Journal of Polymeric Materials and Polymeric Biomaterials2014; 63: 692–697. DOI: 10.1080/00914037.2013.862534.
43.
YangMLiHJavadiA, et al.Multifunctional mesoporous silica nanoparticles as labels for the preparation of ultrasensitive electrochemical immunosensors. Biomaterials2010; 31: 3281–3286.
44.
QiGLiLYuF, et al.Vancomycin-modified mesoporous silica nanoparticles for selective recognition and killing of pathogenic gram-positive bacteria over macrophage-like cells. ACS Appl Mater Interfaces2013; 5: 10874–10881.
45.
LevardCMitraSYangT, et al.Effect of chloride on the dissolution rate of silver nanoparticles and toxicity to E. coli. Environ Sci Technol2013; 47: 5738–5745. DOI: 10.1021/es400396f.
46.
LiuJHurtRH. Ion release kinetics and particle persistence in aqueous nano-silver colloids. Environ Sci Technol2010; 44: 2169–2175. DOI: 10.1021/es9035557.
47.
HussainSJooJKangJ, et al.Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nat Biomed Eng2018; 2: 95–103.
48.
AsgariSPourjavadiAHosseiniSH, et al.A pH-sensitive carrier based-on modified hollow mesoporous carbon nanospheres with calcium-latched gate for drug delivery. Mater Sci Eng C2020; 109: 110517.
49.
TangFLiLChenD. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater2012; 24: 1504–1534.
50.
ZhouYQuanGWuQ, et al.Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B2018; 8: 165–177.
51.
MontgomeryCPBoyle-VavraSAdemPV, et al.Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis2008; 198: 561–570.
52.
TessierPRKeelRAHagiharaM, et al.Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother2012; 56: 2342–2346.
53.
ZhouYNiuCMaB, et al.Inhibiting PSMα-induced neutrophil necroptosis protects mice with MRSA pneumonia by blocking the agr system. Cell Death Dis2018; 9: 362.
54.
ShahangianAChowEKTianX, et al.Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest2009; 119: 1910–1920.
55.
StandifordTJKunkelSLGreenbergerMJ, et al.Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol1996; 59: 24–28.
56.
van der PollTKeoghCVGuiraoX, et al.Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis1997; 176: 439–444.
57.
RijneveldAWFlorquinSBrangerJ, et al.TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol2001; 167: 5240–5246.
58.
AndradeFRafaelDVideiraM, et al.Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev2013; 65: 1816–1827.
59.
FerdousZNemmarA. Health impact of silver nanoparticles: a review of the biodistribution and toxicity following various routes of exposure. Int J Mol Sci2020; 21: 2375.
60.
YinIXZhangJZhaoIS, et al.The antibacterial mechanism of silver nanoparticles and its application in dentistry. Int J Nanomed2020; 15: 2555–2562.
61.
GreulichCBraunDPeetschA, et al.The toxic effect of silver ions and silver nanoparticles towards bacteria and human cells occurs in the same concentration range. RSC Adv2012; 2: 6981–6987.
62.
MediciSPeanaMNurchiVM, et al.Medical uses of silver: history, myths, and scientific evidence. J Med Chem2019; 62: 5923–5943. DOI: 10.1021/acs.jmedchem.8b01439.
63.
ZhuYXuJWangY, et al.Silver nanoparticles-decorated and mesoporous silica coated single-walled carbon nanotubes with an enhanced antibacterial activity for killing drug-resistant bacteria. Nano Res2020; 13: 389–400.
64.
BetalaPAAppugounderSChakrabortyS, et al.Rapid colorimetric detection of proteins and bacteria using silver reduction/precipitation catalyzed by gold nanoparticles. Sens Instrum Food Qual Saf2008; 2: 34–42.
65.
KaushalSPinnakaAKSoniS, et al.Antibody assisted graphene oxide coated gold nanoparticles for rapid bacterial detection and near infrared light enhanced antibacterial activity. Sensor Actuator B Chem2021; 329: 129141.
66.
KellAJStewartGRyanS, et al.Vancomycin-modified nanoparticles for efficient targeting and preconcentration of gram-positive and gram-negative bacteria. ACS Nano2008; 2: 1777–1788. DOI: 10.1021/nn700183g.
67.
HagbaniTAYadavHMoinA, et al.Enhancement of vancomycin potential against pathogenic bacterial strains via gold nano-formulations: a nano-antibiotic approach. Materials2022; 15: 1108.
68.
AlvenSAderibigbeBABalogunMO, et al.Polymer-drug conjugates containing antimalarial drugs and antibiotics. J Drug Deliv Sci Technol2019; 53: 101171. DOI: 10.1016/j.jddst.2019.101171.
69.
AjalloueianFAsgariSGuerraPR, et al.Amoxicillin-loaded multilayer pullulan-based nanofibers maintain long-term antibacterial properties with tunable release profile for topical skin delivery applications. Int J Biol Macromol2022; 215: 413–423. DOI: 10.1016/j.ijbiomac.2022.06.054.
70.
KalhapureRSSulemanNMocktarC, et al.Nanoengineered drug delivery systems for enhancing antibiotic therapy. J Pharmaceut Sci2015; 104: 872–905. DOI: 10.1002/jps.24298.
71.
Malaekeh-NikoueiBFazly BazzazBSMirhadiE, et al.The role of nanotechnology in combating biofilm-based antibiotic resistance. J Drug Deliv Sci Technol2020; 60: 101880.
72.
KlasenHJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns2000; 26: 131–138. DOI: 10.1016/s0305-4179(99)00116-3.
73.
SondiISalopek-SondiB. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci2004; 275: 177–182. DOI: 10.1016/j.jcis.2004.02.012.
74.
PaneysarJSBartonSAmbreP, et al.Novel temperature responsive films impregnated with silver nano particles (Ag-NPs) as potential dressings for wounds. J Pharmaceut Sci2022; 111: 810–817. DOI: 10.1016/j.xphs.2021.11.009.
75.
KaweeteerawatCNa UbolPSangmuangS, et al.Mechanisms of antibiotic resistance in bacteria mediated by silver nanoparticles. J Toxicol Environ Health2017; 80: 1276–1289.
76.
AsgariSMohammadi ZiaraniGBadieiA, et al.Electrospun Ag-decorated reduced GO-graft-chitosan composite nanofibers with visible light photocatalytic activity for antibacterial performance. Chemosphere2022; 299: 134436. DOI: 10.1016/j.chemosphere.2022.134436.
77.
BrownANSmithKSamuelsTA, et al.Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol2012; 78: 2768–2774.
78.
LuJWangYJinM, et al.Both silver ions and silver nanoparticles facilitate the horizontal transfer of plasmid-mediated antibiotic resistance genes. Water Res2020; 169: 115229.
79.
PedrazaDDíezJColillaM, et al.Amine-functionalized mesoporous silica nanoparticles: a new nanoantibiotic for bone infection treatment. Biomedical glasses2018; 4: 1–12.
80.
Garcia-FernandezASancenonFMartinez-ManezR. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv Drug Deliv Rev2021; 177: 113953.
81.
StephenSGorainBChoudhuryH, et al.Exploring the role of mesoporous silica nanoparticle in the development of novel drug delivery systems. Drug Deliv Transl Res2022; 12: 105–123.
82.
LiuJLiSFangY, et al.Boosting antibacterial activity with mesoporous silica nanoparticles supported silver nanoclusters. J Colloid Interface Sci2019; 555: 470–479. DOI: 10.1016/j.jcis.2019.08.009.
83.
TaviraMMousavi-KhattatMShakeranZ, et al.PCL/gelatin nanofibers embedded with doxorubicin-loaded mesoporous silica nanoparticles/silver nanoparticles as an antibacterial and anti-melanoma cancer. Int J Pharm2023; 642: 123162. DOI: 10.1016/j.ijpharm.2023.123162.
84.
LiYYanYWangJ, et al.Preparation of silver nanoparticles decorated mesoporous silica nanorods with photothermal antibacterial property. Colloids Surf A Physicochem Eng Asp2022; 648: 129242.
85.
PatwekarMPatwekarFAlghamdiS, et al.Vancomycin as an antibacterial agent capped with silver nanoparticles: an experimental potential analysis. BioMed Res Int2022; 2022: 3682757.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
